DuPont Launches Chinese-Language Regional Website for DuPont™ Liveo™ Healthcare Solutions Brand

The new site will meet the demand for high-quality, high-performance healthcare products in China

WILMINGTON, Del., October 11, 2022 /PRNewswire-PRWeb/ — DuPont (NYSE: DD) announced the launch of, its new regional DuPont™ Liveo™ Healthcare Solutions website serving Greater China. The company has actively expanded its global footprint – with the new website being the latest development – to better serve customers in China and around the world.

The Liveo™ website helps customers find product and application information in Chinese for the three markets Liveo™ serves:

  • Biopharmaceutical processing – enabling cost-effective and safe manufacturing of biologicals used in innovative drugs and vaccines with a wide range of Liveo™ pharmaceutical tubing and overmolded assemblies

  • Pharmaceutical Solutions – enabling new routes of safe and effective therapeutic drug delivery with a unique offering of topical and transdermal solutions, as well as gastrointestinal active pharmaceutical ingredients (APIs)

  • Medical Devices – enabling safe, convenient and effective point-of-care diagnostics, monitoring and treatment with an expanded range of specialty medical adhesives and elastomers to support the trend of connected devices and wearables.

DuPont has also made other recent investments in the China market. In August, DuPont announced an increase in production capabilities for its silicone Liveo™ pharmaceutical tubing by adding manufacturing capacity in eastern China. Manufacturing expansion aims to meet demand for high purity biopharmaceutical tubes in Greater China.

“DuPont is committed to continued investment in healthcare capabilities to meet the needs of our many rapidly growing customers, both in China and elsewhere in the world,” said DuPont Healthcare & Specialty Lubricants Global Business Director Eugenio Toccalino. “We hope to enable our customers to grow, innovate and save lives while continuing our long-term commitment to the healthcare industry.”

The new website can be viewed at For information on Liveo™ products and applications in English, visit

About DuPont™ Liveo™ Healthcare Solutions
DuPont™ Liveo™ is a globally recognized technology leader for a wide range of innovations in medical devices, biopharmaceutical treatment and pharmaceutical solutions. DuPont’s high-performance materials help create safer healthcare environments and protect the health of patients and healthcare providers worldwide. We help enable smarter healthcare and positive patient outcomes. More information on

About DuPont Electronics and Industry
DuPont Electronics & Industrial is a global supplier of new technologies and performance materials to the semiconductor, printed circuit board, display, digital and flexographic printing, healthcare, aerospace, industry and transport. From state-of-the-art technology centers around the world, teams of talented researchers and application experts work closely with customers, delivering technical solutions, products and services to enable next-generation technologies.

About DuPont
DuPont (NYSE: DD) is a global innovation leader with materials and technology solutions that help transform industries and everyday life. Our people apply diverse science and expertise to help customers advance their best ideas and deliver critical innovations in key markets such as electronics, transportation, construction, water, worker health and safety . For more information about the company, its businesses and its solutions, visit Investors can access the information included in the Investor Relations section of the website at


On November 2, 2021, DuPont announced that it has entered into definitive agreements to acquire Rogers Corporation (“Rogers”), (the “Planned Acquisition of Rogers”). On January 25, 2022, Rogers shareholders approved the transaction. Closing is expected by the end of the second quarter of 2022, subject to regulatory approvals and customary closing conditions.

On February 18, 2022, DuPont announced that it has entered into definitive agreements to divest the majority of its Mobility & Materials segment, excluding certain Advanced Solutions and Performance Resins businesses, to Celanese Corporation (“Celanese”), (the “M&M Divestiture”) . Closing is expected in late 2022, subject to regulatory approvals and customary closing conditions.

The Company also announced the February 18, 2022 that its Board of Directors has approved the sale of the Delrin® acetal homopolymer (H-POM) business. In addition to entering into definitive agreements, the Company anticipates that the closing of the sale of Delrin® will be subject to regulatory approvals and other customary closing conditions (the “Delrin® Business Divestiture” and, together with the M&M, the “M&M Assignments”).

Caution Regarding Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as fine. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect”, “anticipate”, “intend”, “plan ‘, ‘believe’, ‘seek’, ‘see’, ‘will fly’, ‘would’, ‘target’ and similar expressions and variations or negatives of these words.

Forward-looking statements address matters that are, to varying degrees, uncertain and subject to risks, uncertainties and assumptions, many of which are beyond DuPont’s control, that could cause actual results to differ materially from those expressed in forward-looking statements. . Forward-looking statements are not guarantees of future results. Some of the important factors that could cause DuPont’s actual results to differ materially from those projected in these forward-looking statements include, but are not limited to: (i) the parties’ ability to meet expectations regarding the timing, completion and accounting and tax treatments of the divestiture of M&M to Celanese, including (x) any failure to obtain necessary regulatory approvals, anticipated tax treatment or to satisfy any of the other conditions of the proposed transaction, ( (y) the possibility that unforeseen liabilities, future capital expenditures, revenues, expenses, profits, synergies, economic performance, indebtedness, financial condition, losses, future prospects, strategies business and management could affect the value, timing or continuation of the proposed transaction, and (z) the risks and costs and the continuation e and/or the implementation, timing and impacts on business operations of the separation of the business segments in connection with the sale of M&M to Celanese, (ii) the t the timing and outcome of the divestiture of the Delrin® business, including entering into definitive agreements, and the risks, costs and ability to realize the benefits of the continued divestiture of the Delrin® business; (iii) the ability to obtain anticipated tax treatments in connection with mergers, acquisitions, divestitures and other portfolio modification actions and the impact of changes in applicable tax and other laws; (iv) compensation for certain liabilities inherited from the past; (v) the risks and costs associated with each party’s respective performance and the impact of the agreement to share future eligible PFAS costs by and between DuPont, Corteva and Chemours; (vi) the inability to close in a timely manner on the terms anticipated (or at all), realize the anticipated benefits, and effectively manage and achieve the synergies and operational efficiencies anticipated in connection with the mergers, acquisitions, divestitures and other portfolio changes, including the planned acquisition of Rogers and divestitures of M&M; (vii) risks and uncertainties, including increased costs and the ability to obtain raw materials and meet customer needs, related to impacts or disruptions to the supply chain and operations, which may result from, among other events, the COVID-19 pandemic and actions in response to it, and geopolitical and weather events; (viii) ability to offset increases in the cost of inputs, including raw materials, energy and logistics; and (ix) other risks to DuPont’s business and operations; each as more fully explained in DuPont’s most recent annual report and in subsequent current and periodic reports filed with the United States Securities and Exchange Commission. Factors not listed may present additional material impediments to the making of forward-looking statements. The consequences of material differences in results from those anticipated in the forward-looking statements could include, among other things, business or supply chain disruption, operational problems, financial loss, legal liability to third parties and similar risks, each of which could have a material adverse effect on DuPont’s consolidated financial condition, results of operations, credit rating or liquidity. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. DuPont undertakes no obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, if circumstances change, except as securities laws and other applicable laws require it.

DuPont™, the DuPont oval logo, and all trademarks and service marks designated ™, SM, or ® are the property of affiliates of DuPont de Nemours, Inc., unless otherwise noted.


For more information, contact:
Fiona Paul Pinter
Global Communications Leader, Healthcare
+41 79 5713084
[email protected]


Suggested caption:
Recently launched offers product information and resources in Chinese to customers of Greater China.

Media Contact

Fiona Paul PinterDuPont, +41 79 5713084, [email protected]


Comments are closed.